Lieping Chen
Co-Founder & Chairman of Scientific Advisory BoardDr. Lieping Chen, PhD, MD is Founder and Scientific Collaborator of DynamiCure Biotechnology, LLC. Dr. Chen serves as the Member of Scientific Advisory Board of Normunity Inc. Dr. Chen is Member of Scientific Advisory Board at OncoC4, Inc. He has been Independent Non-Executive Director at Sino Biopharmaceutical Limited since June 17, 2026. He serves as a Member of Advisory Board at OmniCyte, LLC. He has been Independent Non-Executive Director at Topalliance Biosciences Inc. Dr. Chen was an Independent Non-Executive Director at Shanghai Junshi Biosciences Co. Ltd. since June 24, 2018 until June 30, 2023. He is a Co-Founder of NextCure, Inc. and serves as Chairman of Scientific Advisory Board. He serves as Member of Science Advisory Board at ImmunGene Inc. Dr. Chen's accomplishments and expertise in the immuno-oncology field have led to revolutionary new therapies for the treatment of cancer including the development of PD-1/PD-L1 antibody therapies. Dr. Chen is the United Technologies Corporation Professor in Cancer Research, Co-Director of the Cancer Immunology Program at the Yale Cancer Center and a Professor of immunobiology, dermatology and medicine (Medical Oncology) at the Yale University School of Medicine. His research through the 1990s demonstrated the first proof-of-concept identifying membrane proteins that can control T cell function and that these membrane proteins could be targets for cancer therapeutics. Before joining the Yale University School of Medicine, Dr. Chen was at the Mayo Clinic where he was the first to discover a molecule that is now known as PD-L1 and demonstrate that its activity can cause T cell death and protect cancer cells from an immune response against them. He then showed that blocking PD-L1’s interaction with PD-1 with monoclonal antibodies improved the body's ability to fight cancer. In 2006, he moved to Johns Hopkins Medical Institute where he developed a PD-L1 biomarker. The totality of this work led to anti-PD-1/PD-L1 therapy, which have revolutionized cancer treatment. Dr. Chen made other important discoveries elucidating various molecular pathways with immune modulatory functions and these discoveries led to the clinical development of many therapeutic agents. Dr. Chen earned his Ph.D. from Drexel University in Pathology and Laboratory Medicine in 1989, his M.S. from Beijing Union Medical College in Immunology and his M.D. from Fujian Medical College. He has published more than 350 research articles, reviews and book chapters. He has received several awards and professional recognitions including William B. Coley Award (2014), Warren Alpert Foundation Prize (2017) and Giants of Cancer Care (2018). Dr. Chen was a Scientific Founder and Board Observer of Amplimmune, Inc. He was Scientific Advisory Board of Zai Lab Limited until August 2025 and was its Member of Oncology Scientific Advisory Board since August 2025 until July 2026.
公司職務
- 公司名稱NextCure, Inc.股票代碼NXTC職務Co-Founder & Chairman of Scientific Advisory Board共事同僚
- MSMichael S. RichmanCo-Founder, CEO, President & Director
- DSDavid S. KabakoffIndependent Chairman of the Board
- TMTimothy MayerChief Operating Officer
- SPSteven P. CobournChief Financial Officer
- KGKevin G. ShawSenior VP & General Counsel
- EVElaine V. JonesIndependent Director
- SWStephen W. WebsterIndependent Director
